TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04734080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol 5mg Cap
Description: Dronabinol is a synthetic tetrahydrocannabinol (THC) agent approved for nausea and vomiting with chemotherapy and as an appetite stimulant in AIDS patients.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Non-active placebo
Study: NCT06451627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine ( 50mg, dissolved in 50ml normal saline ) will be infused at a speed of 0.3mg / kg / h during surgery .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Saline will be infused at a speed of 0.3mg / kg / h during surgery .
Study: NCT05147116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleeping in a tent
Description: Participants will spend 10 consecutive nights of sleeping in a tent

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sleeping in a tent
Description: Participants will spend 10 consecutive nights of sleeping in a tent
Study: NCT06646042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuzatrelvir
Description: 2x 300 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuzatrelvir
Description: 2x 300 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbamazepine ER
Description: 100 mg BID (Day 1-3) 200 mg BID (Day 4-7) 300 mg BID (Day 8-15)
Study: NCT06559150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Ensifentrine Suspension; 3 mg
Description: Administered by a standard jet nebulizer, twice daily for a minimum of 24 weeks and up to a maximum of 156 weeks (3 years)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized Placebo Solution
Description: Administered by a standard jet nebulizer, twice daily for a minimum of 24 weeks and up to a maximum of 156 weeks (3 years)
Study: NCT06285448

Intervention type: DRUG
Intervention: Lecanemab
Description: Bi-weekly infusions of lecanemab \[exposure\].
Study: NCT05810298

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Asana Practice
Description: Yogasana training will be comprised of active movements when standing. Spine and limbs stretches eccentrically respecting the movement patterns of body without pushing limits. Transition in between poses will be synchronized with breathing pattern in zero resistance flow. The exercises will be done 2 days a week online under the supervision of physiotherapist. Total duration of standing poses training will last for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asana Practice
Description: Yogasana training will be comprised of active movements when standing. Spine and limbs stretches eccentrically respecting the movement patterns of body without pushing limits. Transition in between poses will be synchronized with breathing pattern in zero resistance flow. The exercises will be done 2 days a week online under the supervision of physiotherapist. Total duration of standing poses training will last for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pranayam Practice (Rhythmic regulated breathing)
Description: Breathing exercises will be comprised of diaphragmatic breathing, holding the breath after inhaling deeply and exhaling passively or exhaling actively by contracting abdominal muscles and inhaling passively. The exercises will be done 2 days a week online under the supervision of physiotherapist. Total duration of breathing exercises will last for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pranayam Practice (Rhythmic regulated breathing)
Description: Breathing exercises will be comprised of diaphragmatic breathing, holding the breath after inhaling deeply and exhaling passively or exhaling actively by contracting abdominal muscles and inhaling passively. The exercises will be done 2 days a week online under the supervision of physiotherapist. Total duration of breathing exercises will last for 4 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Education Program
Description: The aim of the education is to increase awareness of subjects who are chronical smokers. The subject education will be performed at least once via face to face interview. Education topics will be covered basic information about harmful effects of habitual smoking and how to reduce the side effects of nicotine withdrawal.
Study: NCT05374291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day (oral)
Description: Patients take 10 mg dapagliflozin or matching placebo once daily in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients take 10 mg dapagliflozin or matching placebo once daily in the morning
Study: NCT06153095

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMPT-514
Description: CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
Study: NCT05455307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allium ureteral stent
Description: observe the effficacy and safety of long-term self expanding ureteral stents for treating refractory ureteral stricture
Study: NCT05579223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Hydromorphone Mono Injection
Description: Experimental Drug: Hydromorphone Hydrochloride Injection. Administration: subarachnoid space mono bolus inject, + 5% glucose injection diluted to 75 μg:1.5ml, Speed ≤ 0.5 ml/s

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intrathecal Placebo Mono Injection
Description: Placebo: 5% glucose injection. Administration: subarachnoid space mono bolus inject, 1.5ml, Speed ≤ 0.5 ml/s
Study: NCT05921357

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire and examine

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire and examine

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire and examine
Study: NCT06400134

Intervention type: OTHER
Intervention: Cognitive Function
Description: The Standardized Mini Mental Test (SMMT) was used to evaluate the cognitive status of the geriatric individuals'. In the test, which has a total score of 30, those with a score of 24 or less are recommended to be evaluated for dementia.
Study: NCT05311527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urolift
Description: Urolift Implant
Study: NCT06400134

Intervention type: OTHER
Intervention: Physical Performance
Description: The Brief Physical Performance Battery (BPPB) was used to assess the physical performance of geriatric individuals. All three physical performance measures (balance, walking speed, getting up from the chair) were scored between 0-4 according to the duration of the activity, these scores were summed and the total score was determined between 0 (poor) and 12 (very good).

Intervention type: OTHER
Intervention: Grip Strength
Description: Muscle strength was assessed with a hand grip dynamometer. In the geriatric individuals, less than 30 kg for men and less than 20 kg for women was considered as low hand grip strength.

Intervention type: OTHER
Intervention: Walking speed
Description: Walking speed was assessed with the 6-metre walk test. Speed was calculated by dividing each known distance by the time it took for each individual, on each trial, to walk from the start to the end points marked on the floor and then converting to m/s.

Intervention type: OTHER
Intervention: Mobility
Description: The Time up Go test (TUG) was used for mobility. The risk of falling increases with increasing duration.

Intervention type: OTHER
Intervention: Fraility
Description: Frailty assessment was performed using the FRAIL scale.The scale was scored by giving 0 or 1 point according to the answer given. The higher the score, the greater the fraility.
Study: NCT05311527

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR
Description: Stereotactic Body Radiation Therapy for prostate cancer
Study: NCT05804916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface Guided Radiation Therapy (SGRT)
Description: SGRT and DIBH those two devices could be combined together to improve the accuracy in radiation therapy position and heart protection
Study: NCT06634251

Intervention type: OTHER
Intervention: No intervention
Description: This study is purely observational and does not involve any direct intervention. It utilizes retrospective analysis of computed tomography (CT) scans to simulate the fluoroscopic visualization and screw placement technique in the anterior column fixation corridor (ACFC) of the acetabulum. The objective is to define the optimal antegrade entry point and assess anatomical parameters without performing any physical intervention on the participants.

Intervention type: OTHER
Intervention: No intervention
Description: This study is purely observational and does not involve any direct intervention. It utilizes retrospective analysis of computed tomography (CT) scans to simulate the fluoroscopic visualization and screw placement technique in the anterior column fixation corridor (ACFC) of the acetabulum. The objective is to define the optimal antegrade entry point and assess anatomical parameters without performing any physical intervention on the participants.
Study: NCT06633510

Intervention type: DEVICE
Intervention: massimo
Description: masimo is a device for the continuous noninvasive measurement of arterial hemoglobin functional oxygen saturation (SpO2), pulse rate (PR), pleth variability index (PVi) and pleth respiratory rate (Rrp) PI (perfusion index).
Study: NCT06533748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally (PO) or intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IT MHA
Description: Given Intrathecal (IT), Age adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or IT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, IV, PO or intramuscular (IM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Mercaptopurine
Description: Given PO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO (participants intolerant to mercaptopurine).
Study: NCT05799313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: At home removal
Description: Removal of PNE lead at home

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In office removal
Description: Removal of PNE lead in the office
Study: NCT05574101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Participants will undergo baseline imaging, followed by two doses of neoadjuvant cemiplimab at a dose of 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days). Then, participants will receive concurrent cemiplimab 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days) concurrently with RT to 70 Gy in 35 fractions over 7 weeks. Thereafter, participants will receive 38 weeks of cemiplimab 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days) for a cumulative total of 12 months of cemiplimab.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Participants will receive radiotherapy to 70 Gy in 35 fractions over 7 weeks concurrently with cemiplimab
Study: NCT06421935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9466
Description: Participants will be administered M9466 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9466
Description: Participants will be administered M9466 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuvusertib
Description: Participants will be administered Tuvusertib orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Participants will be administered with Abiraterone acetate orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone/Prednisolone
Description: Participants will be administered with prednisone/prednisolone orally.
Study: NCT05292586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone Dipropionate/Formoterol Fumarate
Description: Available in pressurized inhalation solution BDP/FF 200/6 µg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone Dipropionate
Description: Available in pressurized inhalation solution BDP 100 µg
Study: NCT05024864

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Urea breath test (UBT)
Description: After fasting for six hours prior to testing, the patient swallows a C13 Urea tablet or solution and waits. After 10 minutes, the patient exhales and breath is collected (breath bag). The production of 13CO2 is measured by a desktop analyzer (infrared mass spectrometry) and active H. pylori infection diagnosis is made based on previously established cut-off levels for H. pylori infection.~In patients tested positive, eradication therapy according to the national society of gastroenterology guidelines will be prescribed at the caring physician's discretion.~Control of successful H. pylori eradication 6 weeks after completed eradication therapy is recommended to the treating physician.~During the period without H. pylori screening, the study´s UBT equipment will not be available.
Study: NCT05687383

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Safe breastfeeding pillow
Description: A randomized controlled trial
Study: NCT05199454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Aerobic exercise training using a treadmill or a bike for 12 weeks, 3 times per week, 60 minutes per session.
Study: NCT05687383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Safe breastfeeding pillow
Description: A randomized controlled trial
Study: NCT05699031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APP
Description: Patients allocated in the app-group will use the newly developed smartphone app te rehabilitate. 5 exercises are provided daily. Daily questionnaires will monitor exercise performance, VAS pain, household activities. Information modules will be sent at specific times.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PHYSICAL THERAPY
Description: Patients allocated in the physio-group will go, twice a week, to a physical therapist of their choice to rehabilitate. The physical therapist will follow the general guidelines provided by the hospital (surgeon).
Study: NCT05011656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seraph-100 + State of the Art Care
Description: Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) manufactured by ExThera Medical Corporation in Martinez, CA. The Seraph 100 filter has been designed and manufactured to reduce residual risks as much as possible to ensure safe usage. Literature search results concluded that heparin-coated medical devices are safe and decrease platelet adhesion without affecting the adsorption of major adhesive proteins. The efficacy, safety, and risk-benefit data of the studies suggest that Seraph 100 is also safe and potentially beneficial by reducing the rate of thrombosis, without its use entailing a risk for patients. The achieved results from the above-mentioned testing and studies support the performance and safety of Seraph 100 consistent with the intended use. ExThera Medical concludes that the known and potential benefits of Seraph 100, when used to treat patients with pathogen associated shock, outweigh the known and potential risks when used according to the intended use.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: State of the Art Care
Description: State of the Art careis defined as the treatment algorithms outlined in the Surviving Sepsis Campaign for the treatment of septic shock, available at https://www.sccm.org/SurvivingSepsisCampaign/Home
Study: NCT06018038

Intervention type: DIAGNOSTIC_TEST
Intervention: Maximal Exercise Capacity, Maximal Oxygen Consumption (VO2max)
Description: Cardiopulmonary Exercise Testing (CPET)

Intervention type: DIAGNOSTIC_TEST
Intervention: Maximal Exercise Capacity, Maximal Oxygen Consumption (VO2max)
Description: Cardiopulmonary Exercise Testing (CPET)
Study: NCT06081283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenobarbital Sodium Injection
Description: \*This drug can only be selected as part of the intervention for the subgroup of patients with a Glasgow Coma Score of 8 or less.~Loading dose 20 mg/kg intravenous. Max dose 1000mg Maintenance dose 4mg/kg/day. Max dose 300mg/day. Adult population Loading dose 20 mg/kg intravenous. Maintenance dose 4mg/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Pediatric population Loading dose 60 mg/kg intravenous. Max dose 4000mg. Maintenance dose 40mg/Kg/day, Max dose 3000mg/day. Adult population Loading dose 2000mg-4000mg intravenous. Maintenance dose 1500mg to 3000mg/day.
Study: NCT06255106

Intervention type: OTHER
Intervention: cast treatment
Description: Surgical intervention vs cast treatment

Intervention type: OTHER
Intervention: cast treatment
Description: Surgical intervention vs cast treatment
Study: NCT06081283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide Injectable Product
Description: Pediatric population Loading dose 10 mg/kg intravenous, Max dose 400mg. Maintenance dose 4mg to 8mg/Kg/day. Max dose 300mg. Adult population Loading dose 200mg to 400mg intravenous. Maintenance dose 200mg to 400mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate Sodium
Description: Pediatric population Loading dose 30mg/kg intravenous. Max dose 3000mg Maintenance dose 20mg to 30mg/Kg/day, Max dose 3000mg/day. Adult population Loading dose 30 mg/kg intravenous. Maintenance dose 20mg to 30mg/Kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphenytoin
Description: Pediatric population Loading dose 20 mg PE/kg intravenous. Max dose 1500mg PE Maintenance dose 4mg PE/Kg/day. Max dose 300mg PE/day. Adult population Loading dose 20 mg/kg intravenous. Max dose 1500mg PE Maintenance dose 4mg PE/Kg/day.
Study: NCT04979910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: a monoclonal antibody (mAb) against interleukin 17A (IL-17A)
Study: NCT06545500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (85 μg)
Description: Administered by a standard jet nebulizer, twice daily for 7 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (42.5 μg)
Description: Administered by a standard jet nebulizer, twice daily for 7 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (14 μg)
Description: Administered by a standard jet nebulizer, twice daily for 7 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by a standard jet nebulizer, twice daily for 7 consecutive days
Study: NCT06250036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single agent zimberelimab
Description: Single agent zimberelimab (PD-1 inhibitor) Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination zimberelimab + domvanalimab
Description: Combination zimberelimab + domvanalimab (TIGIT inhibitor) Q3W
Study: NCT06292013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lepodisiran Sodium
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT05769283

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: Platelet rich plasma (PRP) is autologous blood which has been centrifuged to separate the supernatant resulting in a solution with high concentration of platelets. It is then injected into the anterior vaginal wall and periclitoral area

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal Saline to be injected into the anterior vaginal wall and periclitoral area
Study: NCT05457478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Qardio® smart scale Usage and Evaluation
Description: Weight monitored using a Qardio® smart scale

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05099003

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo a MRI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given orally
Study: NCT05988099

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Complex product
Description: 400 mg of chokeberry extract in liposomal formulation and L-arginine, vitamin E, vitamin A, folic acid, chromium

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chokeberry extract in liposomal formulation
Description: 400 mg of chokeberry extract in liposomal formulation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chokeberry extract in traditional formulation
Description: 400 mg of chokeberry extract in traditional formulation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo